Liver Failure
Conditions
Brief summary
Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.
Interventions
PROCEDUREALF
Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
PROCEDURESALF
The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
PROCEDUREACLF
On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Patients with a diagnosis consistent with liver failure and pre-liver failure: * Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention; * Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L); * Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.
Exclusion criteria
* An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 28-day | 28-day survival rates without liver transplantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease progression | 48 weeks after discharge | Incidence of complications and re-hospitalization at 48 weeks after discharge |
Countries
China
Contacts
Primary ContactYingli He, Pro.
Backup ContactJuan Li, M.D.
Outcome results
None listed